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ABSTRACT 
We examined whether the COVID-19 pandemic has affected the incidence of tuberculosis 
(TB) and influenza in Serbia, a Southeast European country with a low TB incidence rate 
and a mandatory BCG vaccination at birth. The first case of COVID-19 was registered on 
March 6, 2020. Despite the need for a sudden adaptation of the health care system, routines 
of mycobacterial laboratories have never stopped. In 2020, the number of newly diagnosed 
TB patients was significantly lower than expected (p = 0.04), but the number of patients 
with influenza increased when compared to 2019. Although many patients with influenza 
A H1N1 were observed before the beginning of the COVID-19 pandemic, the increment of 
cases could also be a consequence of cases of influenza with COVID-like symptoms detected 
thereafter. It may also be attributed to misclassification of clinical cases that were negative for 
SARS-CoV-2 and reported as influenza. Difficulties to seek medical attention because of the 
COVID-19 pandemic and possible underreporting are considered as reasons for the decline 
in the incidence rate of TB. On the other hand, individual and social measures to prevent 
the spread of SARS-CoV-2 such as wearing face masks, social distancing, lockdown, which 
were strictly applied to COVID-19 patients, health care staffs and most of the population, 
could have hindered TB infections more than the two viral diseases, which appear to be more 
contagious. The increased motivation of the population to protect their health during the 
COVID-19 pandemic provided an opportunity for their effective education. This is crucial 
in further combating TB as a preventable disease.
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INTRODUCTION
COVID-19, an infectious disease caused by the Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2) caused a pandemic that began in Wuhan, 
China, in 2019. The number of infected people in the world is constantly growing. 
By May 2021 there were 3,198,528 deaths among more than 152 million infected 
people worldwide1. 
SARS-CoV-2 primarily affects the respiratory system and the most common 
symptoms are dry cough, fever, fatigue and shortness of breathe. Some patients may 
experience headache, sore throat, myalgia, diarrhea, vomiting, skin rash and loss of 
taste or smell (anosmia)2. This RNA virus uses ACE 2 receptors to enter the host cell. 
These receptors are expressed in lung alveoli, heart, central nervous system, kidney, 
gut and endothelial cells. In these locations, the virus causes extensive damage.
There is a wide spectrum of clinical presentations varying from asymptomatic 
infection and mild flu-like disease to serious life-threatening conditions with severe 
pneumonia, Acute Respiratory Distress Syndrome (ARDS) and sepsis2. In the central 
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nervous system, macrovascular stroke and Guillain-Barré 
syndrome may develop3 and devastating complications 
may lead to neurological sequellae4. Some patients have 
acute kidney injury and conjunctivitis. SARS-CoV-2 
compromises endothelial cells causing microthrombosis 
and occlusion5. The changes in coagulation are reponsible 
for many COVID-19-related deaths. Despite a better 
understanding of COVID-19 that gained strength over time, 
there is still no definitive treatment protocol and the therapy 
is primarily supportive. Corticosteroids, anticoagulants 
and endothelial stabilizers are very important drugs, 
together with antiviral agents, monoclonal antibodies, 
oligonucleotides, peptides and interferons, used against the 
hyperinflammation state that characterizes COVID-19. The 
real solution to mitigate the disease is a suitable vaccine6.
Before the COVID-19 pandemic, tuberculosis (TB), an 
infectious disease caused by Mycobacterium tuberculosis 
complex bacteria, was a top cause of death worldwide, 
especially in underdeveloped countries, which are also 
the most affected by COVID-19. TB was responsible 
for 1.4 million deaths in 20197. One third of the world’s 
population is infected by M. tuberculosis, i.e., they suffer 
from latent TB infection (LTBI). The risk of active TB 
disease in such populations is 5-10%. General symptoms 
of TB (fever, night sweats, weight loss) precede the onset 
of respiratory symptoms (cough, dyspnea, chest pain), so 
that TB can go unnoticed for months, resulting in delayed 
diagnoses and further transmission of bacilli to others in 
the community.
In some patients with synchronous active TB and 
COVID-19, the diagnosis of the latter was established before 
that of tuberculosis8. Although the signs and symptoms of 
COVID-19 and TB can be very similar, the SARS-CoV-2 
infection causes acute symptoms with sudden high fever, 
cough and fatigue that make individuals seek medical 
attention earlier. The high index of suspicion during the 
COVID-19 pandemic has also contributed to faster diagnoses. 
Some infectious diseases like measles and whooping 
cough can seriously disrupt the human immunity, especially 
during the recovery period. It is possible that COVID-19 can 
trigger the transition from LTBI to active TB in a patient, but 
the potential contribution of COVID-19 for the development 
of active TB disease remains unrevealed. The influence of 
a preexisting TB on the onset of severe COVID-19-related 
pneumonia and on the disease outcome should be further 
studied with a larger sample size. The mortality rate of the 
coinfection is 12.3%, which is significantly higher than for 
COVID-19 alone9. The patients at greatest risk are those 
with comorbidities and/or an impaired immune response, 
such as those with HIV coinfection, malignant diseases, 
immunodeficiencies and old age. Other common risk factors 
for the two infectious diseases are malnutrition, smoking 
and alcohol abuse10,11.
Therefore, it is likely that COVID-19 may worsen the 
epidemiological situation of tuberculosis, at least in TB 
endemic areas where poverty greatly contributes to the TB 
prevalences11. The aim of this study was to investigate how 
the COVID-19 pandemic has affected the incidence of TB 
in Serbia during 2020. 
MATERIALS AND METHODS
Serbia lies at the crossroads of Central and Southeast 
Europe between latitudes 41° and 47° N, and longitudes 
18° and 23° E, on the Balkan peninsula. The country went 
through an economic crisis during the 1990s, when a stable 
TB trend took place, instead of the continuous decrease 
that occurred previously. Moreover, the socio-economic 
transition period at the beginning of the 21st century showed 
a gradually decreasing trend of the total TB incidence 
rate7,12. The current rate of 9/100,000 inhabitants places 
Serbia as a low TB incidence country7,13. BCG vaccination 
is mandatory at birth.
The first case of COVID-19 in Serbia was detected 
on March 6, 2020 followed by a rapid increase in the 
number of cases thereafter. The outbreak is still ongoing. 
The total number of cases confirmed by the middle of 
May 2021 was 707,185 with 6,646 deaths among the 
total population of 6,945,235 inhabitants. The mortality 
rate is 0.95%14. Protective measures such as face mask 
wearing (indoors and outdoors), social distancing and 
lockdown were all implemented to stop the spreading of 
the disease. Vaccination against COVID-19 started on 24th 
December, 2020. About 40% of the adult population had 
been vaccinated by May 15th 2021. Despite an immediate 
adaptation of the health care system to respond to the 
COVID-19 pandemic, the routines of laboratories dedicated 
to mycobacterial diagnoses has never been interrupted.
The following laboratory methods are used in Serbia 
to define cases of COVID-19: Real-Time Polymerase 
Chain Reaction (RT-PCR) and the Rapid Antigen Test 
in nasopharyngeal secretions, together with serological 
tests for anti-SARS-CoV-2 IgM and IgG detection. RT 
PCR-negative patients with clinical and radiological signs 
suggestive of COVID-19 are also classified as COVID-19 
without viral confirmation according to U07.2 from the 
International Classification. Concerning tuberculosis, the 
sputum smear for acid fast bacilli, Lowenstein-Jensen 
medium for culturing M. tuberculosis (gold standard), and 
molecular techniques for the identification of mycobacteria, 
including the GeneXpert MTB/RIF (Cepheid Sunnyvale, 
CA, United States) are available. Diagnosis of influenza 
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is performed by RT-PCR of nasopharyngeal swabs and 
serological tests.
To meet the aim of the study, we used the Annual Report 
on Infectious Diseases of the Republic of Serbia for 2018 
and 2019 issued by the Institute of Public Health of Serbia 
“Dr Milan Jovanović Batut” in Belgrade, preliminary data 
for 2020 with special regard to TB and influenza as well 
as the Central TB registry. The population surveillance of 
influenza in the 2020/2021 season started on September 28, 
2020 (40th reporting week to October 4th 2020) with weekly 
monitoring and through summary reports of influenza into 
the 20th week of the following year. Data of this study were 
collected for the first 16 epidemiological weeks of the year 
2021 and therefore were noted as partial. We applied the 
chi-square test to compare observed and expected values 
of incidence rates.
RESULTS
We found a further decline in the incidence rate of TB 
in Serbia, in 2020. The chi-square test showed that the 
value of 4.5/100.000 inhabitants is significantly lower than 
expected when compared to the trend from previous years 
(p = 0.04). At the same time, the number of detected and 
notified cases of influenza has increased when compared 
to the previous year (Table 1). 
DISCUSSION
A similar situation of decreased TB incidence has been 
reported in some other countries. After the onset of the 
COVID-19 pandemic, the number of new cases of TB in 
South Korea decreased by 23-25%15. Many years before the 
COVID-19 pandemic, both Brazil and India faced problems 
with TB control, having some of the highest burdens of TB 
correlated with poverty16. In 2019, 450.000 TB patients in 
India died, more than 1,000 people daily. In April 2020, 
during the COVID-19 pandemic, the number of TB patients 
was half that reported in February of the same year17. In 
China, the number of new TB cases in February 2020 was 
20% lower than that of February 201918. The situation is 
similar in Malaysia and in the Philippines19.
The decreased TB incidence rate that we found in 
2020 could be explained by two main causes: difficulties 
of potentially preexisting TB patients to seek medical 
attention due to the situation of the COVID-19 pandemic, 
and possible underreporting of TB cases for the same 
reason. The need for a sudden reorganization of the health 
care system and the fear of contracting COVID-19 in health 
care facilities might have led some TB patients to prefer 
staying at home17. However, another rational explanation 
for such an impressive decrease of the TB incidence rate 
in Serbia may be related to the proper implementation of 
measures for the prevention of SARS-CoV-2 transmission 
that could have simultaneously contributed to prevent the 
transmission of other airborne infections. 
On the other hand, the increase of the influenza 
incidence rate may indicate a better detection due to 
influenza cases that would not have sought medical attention 
during the previous years, but did so when they presented 
with COVID-19-like symptoms and as a consequence 
were detected and registered. In addition, the increase of 
the influenza incidence rate may be also attributed to the 
misclassification of SARS-CoV-2 cases that were RT-PCR- 
negative despite the clinical signs and symptoms suggestive 
of COVID-19, that may have been reported as influenza. 
Rare cases of coinfection COVID-19 and influenza A has 
also been seen in clinical practice.
Individual measures against the spread of airborne 
infections have been known for a long time in Serbia, but 
have never been applied as strictly as during the COVID-19 
pandemic among all patients, health care staffs and most of 
the general population. They might have been able to stop 
TB more than COVID-19 and influenza, as COVID-19 and 









2014 1,083 15.1 24,973 348.6
2015 962 13.5 40,845 572.7
2016 837 11.8 44,131 622.0
2017 743 10.5 33,787 478.7
2018 695 9.9 171,901 2,388.0
2019 623 9.0 41,072 591.4
2020 302  4.5* 53,237 (partial data) 766.6
*The tuberculosis incidence rate in 2020 was significantly lower than expected (p = 0.04).
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influenza seems to be more contagious than TB20. A similar 
observation about the influence of COVID-19 on TB control 
as a double-edged sword has been reported in China18. 
Apart from COVID-19, TB remains a leading cause of 
mortality among infectious diseases in the world. Preventive 
measures against COVID-19 have been shown to be useful 
in the prevention of TB transmission as well. We have 
highlighted once more the importance of preventive measures 
in TB control, especially individual ones concerning cough 
hygiene and measures of environmental control, especially in 
health care facilities. The COVID-19 pandemic has enhanced 
the motivation for health protection among populations 
and offers a great opportunity for the implementation of 
educational measures aimed at preventing and controlling 
TB. The example of Serbia is illustrative in these terms. 
The lessons we learned from the COVID-19 pandemic may 
be useful in further controlling TB as a preventable disease.
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